Crossmark

Doxazosin versus tamsulosin for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic literature review and network meta-analysis

Crossref DOI link: https://doi.org/10.1007/s00345-025-06122-1

Published Online: 2026-01-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oelke, Matthias

Cornu, Jean-Nicolas

Chopra, Ishveen

Herrmann, Thomas R. W.

Hassan, Tarek
Funding

Funding for this research was provided by:

Viatris
License Information

Text and Data Mining valid from 2026-01-06

Version of Record valid from 2026-01-06
More Information

Article History

Received: 26 March 2025

Accepted: 25 November 2025

First Online: 6 January 2026

Declarations

:

: M. Oelke received speaker honoraria for Male LUTS/BPH from Astellas, GlaxoSmithKline, Lilly, Pfizer, SAJA-Pharma and SUN Pharma, was advisory board member of Apogepha, Astellas, GlaxoSmithKline, Lilly, Mundipharma, Pierre-Fabre, Pfizer and Recordati, received research grants from Astellas, Intuitive and Pfizer, and participated in clinical trials from Apogepha, Astellas, GlaxoSmithKline, Lilly, Pfizer, Recordati and Dr. Schwabe GmbH. M. Oelke is currently employed at Spital Thurgau AG, Thurgau, Switzerland. J.N. Cornu is a consultant companies like Boston scientific, Medtronic, Pfizer. He is a paid speaker and participated as advisory boards for companies like Boston scientific and Medtronic. He has received travel grants from Stimuli technology, Procept biorobotics. I. Chopra is former employee of Pharmerit International, Bethesda, MD, USA. T Herrmann is currently employed at Spital Thurgau AG, Thurgau, Switzerland. T. Hassan is employee of Viatris Inc., New York, NY, USA.

: This review article does not contain studies with human participants or animals performed by the authors.

Document is current

Any future updates will be listed below